Earnings ·
Coya Therapeutics reports Q3 net loss of $10.6M, completes enrollment in ALS trial
COYACoya Therapeutics, Inc.
Coya Therapeutics reported a net loss of $10.6 million for the quarter ended September 30, 2026, compared to a $2.1 million loss in the prior-year period. Research and development expenses rose to $8.6 million from $2.9 million, driven by increased clinical trial costs for COYA 302. The company holds $35.8 million in cash, sufficient to fund operations into late 2027. Coya also announced the completion of enrollment in its Phase 2/3 ALSTARS trial for ALS treatment, with topline data expected in early Q2 2027. Coya Therapeutics is a clinical-stage biotechnology company developing biologics intended to enhance T-cell function in patients with neurodegenerative disorders.